上海药明生物技术有限公司 Wuxi Biologics
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development 2018-12-13 07:30
WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity 2018-12-12 08:08
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million 2018-12-11 15:00
Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million 2018-12-11 09:47
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics 2018-12-10 10:21
WuXi Biologics Wins SCRIP Award for "Best Company in an Emerging Market" 2018-12-06 18:20
WuXi Biologics Wins SCRIP Award for "Best Company in an Emerging Market" 2018-12-06 18:12
WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland 2018-12-05 23:29
WuXi Biologics Selected as Forbes Asia's Best Under A Billion 2018 2018-11-29 21:28
WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies 2018-11-28 19:44
WuXi Biologics Commenced Construction of 1.6 million sq. ft. Biologics Innovation Center in Shanghai 2018-11-22 14:31
WuXi Biologics' Chief Executive Officer Dr. Chris Chen to Serve on Board of Directors at ISPE and Delivered Keynote Speech at 2018 Annual Meeting 2018-11-07 17:51
WuXi Biologics Commenced Construction of 48,000L Biologics Commercial Manufacturing Center in Shijiazhuang 2018-10-31 16:08
WuXi Biologics Congratulates Tychan on Completing Human Safety Studies for the First-in-Class Zika Virus Antibody in Record Speed 2018-10-29 20:10
CANbridge Pharmaceutical and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics 2018-10-23 20:00
I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Three Bispecific Antibody Programs 2018-09-26 19:24
WuXi Biologics Appoints Harvard Professor David R. Liu to Scientific Advisory Board 2018-09-25 08:00
WuXi Biologics Appoints Harvard Professor David R. Liu to Scientific Advisory Board 2018-09-25 08:00
WuXi Biologics' Chief Quality Officer Received Foreign Post Service Award from FDA 2018-09-18 08:08
WuXi Biologics and Inhibrx Enter an Exclusive Partnership for GMP Manufacturing 2018-09-11 08:38
1 5 6 7 8 9